Chiral resolution methods for racemic pharmaceuticals based on cocrystal formation
文献情報
Currently, more than half of available drugs on the market are chiral, and approximately 90% of these drugs are marketed as racemates. When these racemic medications are exposed to the chiral environment of the human body, differences in their activity appear. The enantiomers of a chiral drug may potentially have distinct pharmacokinetic, metabolic, and toxicological features. As a result, regulatory requirements promote the production of enantiopure drugs to reduce the complexity of pharmacodynamics and the administration dose or to eliminate unwanted side effects, while also providing some economic savings by enabling a totally effective pharmaceutical formulation. There are a variety of procedures employed in the pharmaceutical industry for chiral separation of racemic drugs, such as developing de novo enantiomerically pure pharmaceuticals by asymmetric synthesis or chiral resolution of currently available racemic compounds via different approaches like chiral chromatography methods, diastereoisomeric salt formation, and cocrystallization-based methods. This review will focus on cocrystallization techniques such as the generation of host–guest inclusion compounds, diastereomeric cocrystal pairs, enantiospecific cocrystals, conglomerates, ionic cocrystals, and preferential enrichment of cocrystals. Overall, this review outlined the crucial importance of pharmaceutical cocrystals in chiral resolution techniques of racemic compounds.
関連文献
Modular synthesis of multivalent glycoarchitectures and their unique selectin binding behavior
Ilona Papp, Jens Dernedde, Sven Enders, Rainer Haag
DOI: 10.1039/B813414F
Synthesis of Fe3O4/PdO heterodimer nanocrystals in silica nanospheres and their controllable transformation into Fe3O4/Pd heterodimers and FePd nanocrystals
Jongmin Shin, Hakwon Kim, In Su Lee
DOI: 10.1039/B812690A
Shuffling lithiated mixed aggregates: NMR and Car–Parrinello molecular dynamics reveal an unexpected associative pathway
Franck Paté, Hélène Gérard, Hassan Oulyadi, Aurélien de la Lande, Anne Harrison-Marchand, Olivier Parisel, Jacques Maddaluno
DOI: 10.1039/B814961E
Controlled self-sorting in the assembly of ‘multi-gelator’ gels‡
Jamie R. Moffat, David K. Smith
DOI: 10.1039/B818058J
Amplified fluorescence determination of microRNAs in homogeneous solution with cationic conjugated polymers
Zhengping Li, Yongqiang Cheng
DOI: 10.1039/B816614E
Formation of a stannylstannylenevia intramolecular carbene addition of a transient stannaacetylene (RSnCR′)
Katsuyuki Hirai, Hideo Tomioka, Kenkichi Sakamoto, Mitsuo Kira
DOI: 10.1039/B814801E
Synthesis and structural characterisation of a soluble, metastable indium(i) halide complex, [InBr(tmeda)]
Cameron Jones, Andreas Stasch
DOI: 10.1039/B814658F
Palladium-catalysed direct synthesis of benzo[b]thiophenes from thioenols
Kiyofumi Inamoto, Yukari Arai, Kou Hiroya, Takayuki Doi
DOI: 10.1039/B811362A
Simplified methods for the functionalisation of 3-hexoxythiophenes at the 5-position and further reactions to alkynyl and vinyl derivatives
Mike Joachim Zöllner, Ullrich Jahn, Eike Becker, Wolfgang Kowalsky, Hans-Hermann Johannes
DOI: 10.1039/B817089D
The asymmetric total synthesis of (−)-securinine
Bhartesh Dhudshia, Benjamin F. T. Cooper, Charles L. B. Macdonald, Avinash N. Thadani
DOI: 10.1039/B816576A
こちらもおすすめ
1-{3-[5-(エチルカルボンイル)-2,4-ジメチル-1H-ピロロール-3-基]プロパニル}ピペリジン-4-カルボン酸について、適用される法規ガイドラインは何ですか?
この化合物はCAS番号1142209-81-1であり、GHS分類では corrosive (腐食性物質) と classified (分類物質) として指定され...
2,2-二氟-1,3-ベンゾジオキサン-5-カルボキシlic酸とは何ですか?
2,2-二氟-1,3-ベンゾジオキサン-5-カルボキシlic酸は、CAS番号656-46-2の化合物で、化学式はC8H4F2O4です。この化合物は白色の結晶性粉...
8-氯-4-色原酮の代替品はありますか?
8-氯-4-色原酮(CAS番号: 49701-11-3)の代替品には、他の色原酮類似物や、構造が似ている化合物があります。例えば、8-メチル-4-色原酮や、他の...
エチル6,6-ジメチル-4,5,6,7-テトラヒドロ-1H-インドアゼー-3-カルボキシレートとは何ですか?
エチル6,6-ジメチル-4,5,6,7-テトラヒドロ-1H-インドアゼー-3-カルボキシレートは、CAS番号1233243-56-5を有する化合物です。これは有...
4-叔丁基-6-氯-嘧啶に適用される法規ガイドラインは何ですか?
4-叔丁基-6-氯-嘧啶はCAS番号3435-24-3で、GHS分類では毒性物質とみなし、GHSの危険性分類が適用されます。REACH規則では登録が必要で、Eu...
維库溴铵杂质Bはどのように合成されますか?
維库溴铵杂质Bは、アンドロステンデンから始まり、一連の合成反応、包括的な選択性と高い収率で合成されます。具体的には、ブロミド化、酸化、ジマーゼ反応、アミド化など...
2-(4-氟苄基)-吡咯烷の物理化学的性質は何ですか?
CAS番号350017-04-8の2-(4-氟苄基)-吡咯烷は、結晶性の白色粉末です。分子量は199.17 g/molで、水に溶けにくいです。化学反応では比較的...
3-喹啉甲醛(2-チロール-8-エチル)は安全ですか?
3-喹啉甲醛(2-チロール-8-エチル)は一定の毒性を持つため、取扱には注意が必要です。使用する際は適切な防護具を着用し、密閉容器で保管・搬送し、直接的な接触を...
エチル3-(ヒドロキシメチル)-1H-ピロール-2-カルボキシレートはどのように保存すればよいですか?
エチル3-(ヒドロキシメチル)-1H-ピロール-2-カルボキシレートは、室温(25℃)以下で保存し、直射日光を避け、乾燥した環境で保管することが推奨されます。ま...
掲載誌
CrystEngComm

CrystEngComm is the forum for the design and understanding of crystalline materials. We welcome studies on the investigation of molecular behaviour within crystals, control of nucleation and crystal growth, engineering of crystal structures, and construction of crystalline materials with tuneable properties and functions. We publish hypothesis-driven research into… how crystal design affects thermodynamics, phase transitional behaviours, polymorphism, morphology control, solid state reactivity (crystal-crystal solution-crystal, and gas-crystal reactions), optoelectronics, ferroelectric materials, non-linear optics, molecular and bulk magnetism, conductivity and quantum computing, catalysis, absorption and desorption, and mechanical properties. Using Techniques and methods including… Single crystal and powder X-ray, electron, and neutron diffraction, solid-state spectroscopy, spectrometry, and microscopy, modelling and data mining, and empirical, semi-empirical and ab-initio theoretical evaluations. On crystalline and solid-state materials. We particularly welcome work on MOFs, coordination polymers, nanocrystals, host-guest and multi-component molecular materials. We also accept work on peptides and liquid crystals. All papers should involve the use or development of a design or optimisation strategy. Routine structural reports or crystal morphology descriptions, even when combined with an analysis of properties or potential applications, are generally considered to be outside the scope of the journal and are unlikely to be accepted.









![[2',6'-bis(propan-2-yloxy)-[1,1'-biphenyl]-3-yl]dicyclohexylphosphane structure [2',6'-bis(propan-2-yloxy)-[1,1'-biphenyl]-3-yl]dicyclohexylphosphane structure](https://static.chemtradehub.com/structs/787/787618-22-8-dda2.webp)

![Bis[(1,2,3,4,5-eta)-1-(diphenylphosphino)cyclopentadienyl]iron structure Bis[(1,2,3,4,5-eta)-1-(diphenylphosphino)cyclopentadienyl]iron structure](https://static.chemtradehub.com/structs/121/12150-46-8-ecd2.webp)

